Secondary analysis of the GETUG-12 phase 3 trial (413 men, high-risk localised prostate cancer, ADT ± docetaxel-estramustine): after biochemical progression, progression ≥3 vs <3 years from randomisation meant lower risk of a second event (HR 0.49) and metastases (sub-HR 0.41).
Secondary analysisn = 413
Vicier et al. Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12